Diabetes drugs under review

According to diabetes news report, several major diabetes drugs are under review by the Food and Drug Administration. This April, the FDA will review a variety of diabetes treatments, including offerings by Astrazenecan, Bristol-Myers Squibb and Novo Nordisk .
Further applications are expected from Amylin pharmaceuticals in conjunction with Eli Lilly . The Food and Drug Administration are thought to be focusing on heart risks and increasing safety review standards.
The increase in standards are down to major safety concerns surrounding GlaxoSMithKline drug Avandia. How the different drugs fair in the health and safety reviews will largely determine the face of diabetes treatment over the next few years.
The FDA has a responsibility to ensure that all drugs given clearance to go to market are completely safe for people with diabetes to use.